Because of the potential for methemoglobinemia during nitric oxide therapy in newborns, methods are needed to accurately quantify methemoglobin (MetHb) in the presence of the high concentrations of fetal hemoglobin (Hb F), bilirubin, and lipids seen in these patients. Spectral differences between fetal and adult Hbs invalidate assumptions of conventional multiwavelength Hb photometry, so we evaluated an "overdetermined" system (CibaComing Model 270), in which absorbances at seven wavelengths are measured to quantify four Hb derivatives. 
run precision (CV) was <2.2% (n = 10) at each of seven MetHb fractions between 5% and 100%. Measured (y) and expected (x) MetHb fractions in cord blood were in good agreement (y = 1.0200x + 0.100, S = 0). Added bilibrubin (200 mg/L serum) and lipid (30 g/L) did not interfere. No significant differences were seen for adult and cord blood samples with identical MetHb fractions (P = 0.72), whereas a significant difference was noted with an exactly determined system (P = 0.0033). At clinically relevant MetHb fractions (<15%), a trend towards increased values in cord blood was noted with an exactly determined system (y = 1 .052Q,c + 0.7600). We conclude that this overdetermined system measures MetHb accurately in samples from patients with large concentrations of Hb F.
Indexing Terms: nitric oxide/spectrophotometiy/persistentpulmonaiy hypertension of the newborn
Inhaled nitric oxide (NO) is a promising but potentially toxic therapy for persistent pulmonary hypertension of the newborn (PPHN) (1) (2) 2 NO is a potent vasodilator that, because of its short half-life (3-6 s), acts locally on the pulmonary vasculature without producing systemic vasodilation.
NO is a lipophilic gas that readily diffuses into vascular smooth muscle cells, where it binds to the heme moiety of soluble guanylate cyclase (5) . The resulting activation of guanylate cyclase increases guanosine 3',5 '-cyclic monophosphate (cGMP) (5), which decreases free Ca2 concentrations (6, 7) , and therefore produces vasodilation and decreased pressure in the pulmonary circulation. Therapy with NO can produce toxic effects on blood We used the following methods for both adult and fetal blood to produce samples of each with known MetHb fractions. Heparinized blood (-30 mL, adult or cord) was divided equally into six 50-mL centrifuge tubes. In four tubes designated "0% MetHb," cells were washed four times in 40 mL of isotonic saline (NaC1, 0.158 molIL) with 10-mn centrifugations at 1100g. After the last centrifugation, the supernate was aspirated and the specimens were pooled. The volume was brought to -20 mL with saline, and ctHb was determined with a Beckman (Irvine, CA) DU spectrophotometer by the standard cyanmethemoglobin method (13, 14) . The ctHb was also determined on the Model 270 CO-Oximeter.
The other two tubes of untreated whole blood were labeled "100% MetHb," and the cells were washed once and then mixed with 10-15 mg of KNO2 added to each tube to produce MetHb. The tubes were then incubated for 30 mm in a 37#{176}C water bath, followed by three washings (with saline as described above) to remove excess KNO2. After the final centrifugation, the contents of the two incubated tubes were combined, and the volume was brought to ---10 mL with saline. The ctHb was determined as described above. The 0% MetHb and 100% MetHb samples were then brought to the same ctHb value by saline dilution of the sample with the greater ctHb.
Manual determination of MetHb fractions was performed on a Beckman DU spectrophotometer with the Evelyn-Malloy (KCN addition) method (15) . This method is based on the ah'4orbance maximum of MetHb at 630 nm, a property unique to this Hb derivative. The results documented that the 100% MetHb and 0% MetHb samples contained >99% and <2% MetHb, respectively.
The samples were then used to produce samples with MetHb fractions of 0%, 5%, 10%, 15%, 25%, 50%, 75%, and 100%. The accuracy of the dilution for each of these samples was checked by measurements of MetHb by the Evelyn-Malloy method. For determination of absorption spectra, the samples were diluted 231-fold in deionized water. 
To investigate the effects of lipemia, we mixed 0.5 mL of a 200 g/L commercial fat emulsion (Intralipid; Baxter Laboratories, Deerfield, IL) with the bovine serum albumin solution (described above) to a total volume of 10 mL, for a total triglyceride concentration of 30 g/L. Equal parts of this "lipemic serum" and packed erythrocytes with a known MetHb fraction were mixed in triplicate, and each specimen was analyzed twice on the Model 270. A control sample included the same albumin solution and 0.5 mL of isotonic saline in place of the lipids.
Data comparing the measured vs nominal fractions of MetHb were analyzed by regression and analysis of covariance. Analysis of covariance of the results was carried out with the SAS general linear model program with a homogeneity of slopes model (SAS Institute, Cary, NC). The data obtained with the icteric and lipemic samples were assessed with unpaired t-tests.
Results
The first step in these studies was the preparation of samples with known fractions of MetHb. Representative spectra of these samples are shown in Fig. 1 .
The overdetermined system implemented on the Model 270 yielded within-run imprecision (CV) of 0.06-2.16%
and 0.12-1.05% for samples of cord and adult blood, respectively, with MetHb fractions in the range of 5-100%. The precision profiles for MetHb measured in adult and cord blood are shown in Fig. 2A 0.19% and 0.14-1.06%, respectively, at 30-99% oxyhemoglobin (Fig. 2B) . MetHb results were linear for the cord blood samples over the range of 0-15% (r = 1.000).
As shown in Table 1 , the measured (y) and expected The measured MetHb fraction of a cord blood pool prior to addition of bilirubin or Intralipid was 0.82% ± 0.08% (n = 3); values were unchanged after these additions (0.82% ± 0.20% and 0.80% ± 0.09%, respec- HHb at 5% MetHb to -16.9% HHb at 100% MetHb) with corresponding numerically equivalent increases in COHb (1.6% COHb at 5% MetHb to 18.1% COHb at 100% MetHb). The falsely increased COHb fractions in fetal blood measured by the exactly determined multiwavelength Hb photometer that have been previously described (12) were seen on the older Model 282.
Discussion
The present studies document the linearity, precision, and recovery of fetal MetHb measurements with the overdetermined system of the Model 270 COOximeter. As MetHb increased to >25% of the tHb, the agreement with expected values decreased, a phenomenon seen with both the exactly determined and the overdetermined systems. As these MetHb fractions are well above those to be expected in trials of NO therapy, the analysis of data presented here was performed only for MetHb fractions 15%. The use of KNO2 to produce intraerythrocyte MetHb in our experiments also produces NO2MetHb, as described by Van Assendelft and Zijlstra (16) . This Hb derivative has slight spectral differences from MetHb, and must be removed by carefully washing the erythrocytes multiple times with isotonic saline, which effectively converts all NO2Met}Th to MetHb (16) COHb are not likely to be clinically significant, this limitation must be recognized. HHb is not reported on the IL 282, but it too must be incorrectly measured, as the sum of the reported Hb species (Hb02, COHb, and MetHb) progressively increases to >100% as the MetHb fractions increase.
In conclusion, the Ciba-Corning Model 270 COOximeter uses an overdetermined spectrophotometric method to more accurately measure Hb derivatives in the presence of interfering substances and Hb variants.
Our study supports this finding, while suggesting possible inaccuracies with the more commonly used exactly determined systems.
